{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:27:41Z","timestamp":1749097661777,"version":"3.40.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcyt.2024.12.008","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T05:43:17Z","timestamp":1736055797000},"page":"500-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Higher risk of GVHD but better long-term survival: impact of p-ALG versus r-ATG in high-risk hematological malignancy patients following MSDT"],"prefix":"10.1016","volume":"27","author":[{"given":"Lingyan","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9791-6514","authenticated-orcid":false,"given":"Qian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcyt.2024.12.008_bib0001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology[J]","volume":"18","author":"Saad","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.jcyt.2024.12.008_bib0002","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11427-018-9361-2","article-title":"Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission[J]","volume":"62","author":"Liu","year":"2019","journal-title":"Sci China Life Sci"},{"issue":"5","key":"10.1016\/j.jcyt.2024.12.008_bib0003","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","article-title":"Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study[J]","volume":"34","author":"Yu","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.008_bib0004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.2016.145631","article-title":"Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the acute leukemia working party of the European society for blood and marrow transplantation[J]","volume":"102","author":"Giebel","year":"2017","journal-title":"Haematologica"},{"issue":"727","key":"10.1016\/j.jcyt.2024.12.008_bib0005","doi-asserted-by":"crossref","first-page":"eadf8366","DOI":"10.1126\/scitranslmed.adf8366","article-title":"Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects[J]","volume":"15","author":"Prado-Acosta","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.008_bib0006","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update[J]","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.008_bib0007","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation[J]","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.008_bib0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.6004\/jnccn.2023.0007","article-title":"NCCN Guidelines\u00ae Insights: hematopoietic cell transplantation, version 3.2022[J]","volume":"21","author":"Saad","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.jcyt.2024.12.008_bib0009","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jtct.2022.08.012","article-title":"High risk of recurrence of malignancy noted in four-day rATG Regimen after allogeneic PBSCT from matched sibling donors[J]","volume":"28","author":"Wang","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jcyt.2024.12.008_bib0010","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel[J]","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.008_bib0011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbmt.2017.10.007","article-title":"Effect of antithymocyte globulin source on outcomes of HLA-Matched sibling allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia[J]","volume":"24","author":"Chen","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.008_bib0012","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.19205","article-title":"Effectiveness of in vivo T-cell-depleted regimen containing porcine anti-lymphocyte globulin or rabbit anti-thymocyte globulin in preventing acute graft-versus-host disease after haploidentical haematopoietic stem cell transplantation[J]","volume":"204","author":"Xu","year":"2024","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jcyt.2024.12.008_bib0013","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology[J]","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.jcyt.2024.12.008_bib0014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2024.12.008_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis[J]","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jcyt.2024.12.008_bib0016","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management[J]","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jcyt.2024.12.008_bib0017","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.12694","article-title":"Guidelines for the diagnosis and management of adult myelodysplastic syndromes[J]","volume":"164","author":"Killick","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jcyt.2024.12.008_bib0018","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study[J]","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.008_bib0019","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium[J]","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2024.12.008_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report[J]","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.jcyt.2024.12.008_bib0021","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party[J]","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.008_bib0022","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/bmt.2011.66","article-title":"Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis[J]","volume":"47","author":"Hong","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2024.12.008_bib0023","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America[J]","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jcyt.2024.12.008_bib0024","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ajh.27068","article-title":"Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: a single-arm, phase 2 trial[J]","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jcyt.2024.12.008_bib0025","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials[J]","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jcyt.2024.12.008_bib0026","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ajh.27342","volume":"99","author":"Ye","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jcyt.2024.12.008_bib0027","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia[J]","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.12.008_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","article-title":"Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)[J]","volume":"7","author":"Lai","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2212943","article-title":"Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation[J]","volume":"28","author":"Chen","year":"2023","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.jcyt.2024.12.008_bib0030","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","article-title":"Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial[J]","volume":"4","author":"Finke","year":"2017","journal-title":"Lancet Haematol"},{"issue":"29","key":"10.1016\/j.jcyt.2024.12.008_bib0031","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study[J]","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2024.12.008_bib0032","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.bbmt.2017.08.027","article-title":"Comparison of different rabbit anti-thymocyte globulin formulations in allogeneic stem cell transplantation: systematic literature review and network meta-analysis[J]","volume":"23","author":"Gagelmann","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jcyt.2024.12.008_bib0033","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/ajt.12514","article-title":"A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations[J]","volume":"13","author":"Popow","year":"2013","journal-title":"Am J Transplant"},{"issue":"15","key":"10.1016\/j.jcyt.2024.12.008_bib0034","first-page":"4516","article-title":"Human CD4+ CD25+ regulatory T cells suppress NKT cell functions[J]","volume":"63","author":"Azuma","year":"2003","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jcyt.2024.12.008_bib0035","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.175.7.4180","article-title":"Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells[J]","volume":"175","author":"Lim","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.jcyt.2024.12.008_bib0036","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.TP.0000150210.77543.1B","article-title":"Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells[J]","volume":"79","author":"Fang","year":"2005","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.008_bib0037","first-page":"181","volume":"27","author":"Liu","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2024.12.008_bib0038","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","article-title":"Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival[J]","volume":"26","author":"Valc\u00e1rcel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.008_bib0039","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ejh.12214","article-title":"Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients[J]","volume":"92","author":"Hiramoto","year":"2014","journal-title":"Eur J Haematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:24:33Z","timestamp":1744446273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1465324924009678"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.12.008","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher risk of GVHD but better long-term survival: impact of p-ALG versus r-ATG in high-risk hematological malignancy patients following MSDT","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}